Neuren Pharmaceuticals: From New Zealand roots to ASX stardom

Neuren Pharmaceuticals: From New Zealand roots to ASX stardom
Neuren's Melbourne-based CEO Jon Pilcher credits the pharmaceutical firm's breakthrough medications to NZ research. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
It was the best-performing stock on the ASX in 2023, has a market cap of about $2.2 billion, doesn’t have an office, and was founded in New Zealand. Neuren Pharmaceutical’s medication trofinetide became the first US Food and Drug Administration (FDA) approved treatment for the disabling neurological disorder Rett syndrome in March 2023. Rett syndrome is rare, “profoundly debilitating”, and mostly affects female children. It leads to developmental delays and sometimes regressions as the child ages. Neuren s...

More Markets

Argosy swings to $126m profit on valuation rebound
Property

Argosy swings to $126m profit on valuation rebound

The revaluations helped reverse last year's net loss of $54.5m.

Napier Port to pay special dividend after $7.5m settlement
Economy

Napier Port to pay special dividend after $7.5m settlement

The Hawke's Bay port had a strong first half, handling 13.9% more containers.

Infratil’s US renewables foray ‘disappointing’
Infrastructure

Infratil’s US renewables foray ‘disappointing’

Policy uncertainty from the US could shift infrastructure investor’s focus to Asia.

Wine sector has harvest windfall, faces pricing pressures
Primary Sector

Wine sector has harvest windfall, faces pricing pressures

The harvest jumped as much as 39% compared with the prior season.